Corcept Therapeutics Incorporated (LON:0I3Q)

Corcept Therapeutics Statistics

Total Valuation

LON:0I3Q has a market cap or net worth of GBP 3.15 billion. The enterprise value is 2.77 billion.

Market Cap	3.15B
Enterprise Value	2.77B

Important Dates

The next estimated earnings date is Wednesday, February 18, 2026.

Earnings Date	Feb 18, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	105.19M
Shares Outstanding	n/a
Shares Change (YoY)	+7.55%
Shares Change (QoQ)	-0.87%
Owned by Insiders (%)	11.58%
Owned by Institutions (%)	66.49%
Float	86.83M

Valuation Ratios

The trailing PE ratio is 40.43 and the forward PE ratio is 69.59.

PE Ratio	40.43
Forward PE	69.59
PS Ratio	5.71
PB Ratio	6.70
P/TBV Ratio	6.70
P/FCF Ratio	25.94
P/OCF Ratio	25.90
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 54.33, with an EV/FCF ratio of 22.81.

EV / Earnings	35.55
EV / Sales	5.10
EV / EBITDA	54.33
EV / EBIT	57.60
EV / FCF	22.81

Financial Position

The company has a current ratio of 3.14, with a Debt / Equity ratio of 0.01.

Current Ratio	3.14
Quick Ratio	2.85
Debt / Equity	0.01
Debt / EBITDA	0.09
Debt / FCF	0.04
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is 16.70% and return on invested capital (ROIC) is 25.38%.

Return on Equity (ROE)	16.70%
Return on Assets (ROA)	5.10%
Return on Invested Capital (ROIC)	25.38%
Return on Capital Employed (ROCE)	10.07%
Weighted Average Cost of Capital (WACC)	5.51%
Revenue Per Employee	1.10M
Profits Per Employee	155,716
Employee Count	500
Asset Turnover	0.92
Inventory Turnover	1.31

Taxes

Income Tax	-13.09M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -41.86% in the last 52 weeks. The beta is 0.23, so LON:0I3Q's price volatility has been lower than the market average.

Beta (5Y)	0.23
52-Week Price Change	-41.86%
50-Day Moving Average	57.46
200-Day Moving Average	69.74
Relative Strength Index (RSI)	37.01
Average Volume (20 Days)	5,078

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	5.07

Income Statement

In the last 12 months, LON:0I3Q had revenue of GBP 551.39 million and earned 77.86 million in profits. Earnings per share was 0.65.

Revenue	551.39M
Gross Profit	541.43M
Operating Income	48.78M
Pretax Income	65.85M
Net Income	77.86M
EBITDA	49.63M
EBIT	48.78M
Earnings Per Share (EPS)	0.65

Balance Sheet

The company has 313.71 million in cash and 4.73 million in debt, with a net cash position of 385.27 million.

Cash & Cash Equivalents	313.71M
Total Debt	4.73M
Net Cash	385.27M
Net Cash Per Share	n/a
Equity (Book Value)	470.10M
Book Value Per Share	4.47
Working Capital	274.41M

Cash Flow

In the last 12 months, operating cash flow was 121.54 million and capital expenditures -209,791, giving a free cash flow of 121.33 million.

Operating Cash Flow	121.54M
Capital Expenditures	-209,791
Free Cash Flow	121.33M
FCF Per Share	n/a

Margins

Gross margin is 98.19%, with operating and profit margins of 8.85% and 14.32%.

Gross Margin	98.19%
Operating Margin	8.85%
Pretax Margin	11.94%
Profit Margin	14.32%
EBITDA Margin	9.00%
EBIT Margin	8.85%
FCF Margin	22.01%

Dividends & Yields

LON:0I3Q does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-7.55%
Shareholder Yield	-7.55%
Earnings Yield	2.47%
FCF Yield	3.85%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

LON:0I3Q has an Altman Z-Score of 24.03 and a Piotroski F-Score of 5.

Altman Z-Score	24.03
Piotroski F-Score	5